Bio-Reference Laboratories, Inc. Retains Services of GMF Relations.

ELMWOOD PARK, N.J.,--(BUSINESS WIRE)--Oct. 12, 1999--

Bio-Reference Laboratories, Inc. (Nasdaq:BRLI), announced that it has retained the services of GMF Relations to develop and implement a capital market communications program for the Company.

Bio-Reference is the largest independent clinical laboratory in the Northeast with projected annual revenues of over $50 million. GMF Relations will begin work immediately to help raise the profile of Bio-Reference Laboratories with media and other audiences as it transitions to a Health Services and Information Company.

Based in Woodbury, New York, GMF Relations, Inc. is a financial relations firm that specializes in managing investor relations for small cap companies. "The management team at BRLI is well-seasoned with strengths across all spectrums of its industry," said Gary Frank, president of GMF Relations. "I look forward to working with this talented, entrepreneurial group as they strive to utilize leading-edge information technology sciences to enhance medical management strategies."

"We are very pleased that GMF Relations will be working with us to help broaden Bio-References' exposure to key investors and the financial media, " said Dr. Marc Grodman, Chief Executive Officer of Bio-Reference. "We have a strong business story to tell as we leverage off the strengths of the clinical laboratory to enhance our services. We are confident that a targeted, proactive outreach will enhance shareholder value." Dr. Grodman concluded.

Bio-Reference has recently announced that it is in the process of forming a medical management company that will utilize medical claims, pharmacy and laboratory data to improve the efficacy of medical care. The company also announced the drug screen website, WWW.DRUGSCREENLAB.COM, as the base of its drug testing services.

Bio-Reference is a multi-faceted Health Services and Information Company which includes a highly automated computer-driven clinical laboratory serving markets in the New York/Tri-State metropolitan area. The Company performs sophisticated testing procedures, in addition to high volume routine testing areas such as clinical chemistry, serology, microbiology, hematology, cytology, and anatomic pathology.

Statements included within this news release that are historical in nature constitute forward-looking statements for the purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Investors are cautioned that this news release contains certain such forward-looking statements that involve substantial risks and uncertainties. When used, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company or its management are intended to identify such forward-looking statements. The Company's actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Further management discussion of risks and uncertainties can be found in the Company's quarterly filing with the Securities and Exchange Commission and other periodic filings.